Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade
Background Immune checkpoint antibody blockade is an emerging therapeutic option for treating certain cancers including melanoma. This therapy is associated with dermatologic and systemic toxicities, some of which are more severe than others and may require withholding therapy. Case reports We repor...
Gespeichert in:
| Veröffentlicht in: | International journal of dermatology 2019-09, Vol.58 (9), p.1045-1052 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1052 |
|---|---|
| container_issue | 9 |
| container_start_page | 1045 |
| container_title | International journal of dermatology |
| container_volume | 58 |
| creator | Mauzo, Shakuntala H. Tetzlaff, Michael T. Nelson, Kelly Amaria, Rodabe Patel, Sapna Aung, Phyu P. Nagarajan, Priyadharsini Torres‐Cabala, Carlos A. Diab, Adi Prieto, Victor G. Curry, Jonathan L. |
| description | Background
Immune checkpoint antibody blockade is an emerging therapeutic option for treating certain cancers including melanoma. This therapy is associated with dermatologic and systemic toxicities, some of which are more severe than others and may require withholding therapy.
Case reports
We report two patients with melanocytic nevi that regressed with pembrolizumab therapy. The first patient had stage IV BRAF K601E/L584F mutant melanoma that developed a regressed melanocytic nevus while being treated with pembrolizumab. The second patient had stage III BRAF V600R mutant melanoma that was treated with pembrolizumab and dabrafenib, and also developed a regressed melanocytic nevus. Both patients had good response to therapy and stable disease at 8 and 12 months of treatment, respectively.
Results
Regressed melanocytic nevi were observed in both patients treated with pembrolizumab for advance‐stage melanoma. Immunohistochemical analysis of a regressed melanocytic nevus was associated with an inflammatory infiltrate rich in CD8+ T cells and CD163+, CD11c+ histiocytes.
Conclusion
Regressed melanocytic nevi are an emerging dermatologic effect from pembrolizumab therapy. |
| doi_str_mv | 10.1111/ijd.13833 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2267661759</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2267661759</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-185c7356dfd667cf079402b29ce9a478a12b19e4cf7d77eb69b0fa1d647253f13</originalsourceid><addsrcrecordid>eNp1kE1LHTEUQIMo-mq76B8oAVcuRifJTPLirmg_FKFQ2vWQj5tnnpPJmMxUpn-jf9i0zwpd9G7ChcMJ9yD0ltRnpMy539ozwtaM7aEVYbytGs7oPlrVNSGVrFt5hF7lvC0ro6Q5REdUkpYK2q7Qr6-wSZAzWBygV0M0y-QNHuCHxxlMHKxKC54iHiHoFHv_cw5K4-kOkhqXC6wGDAHSxg-bfwQWUlBT7OOmLOAcmAm7FAP2IcwDYHMH5n6MfpiKYvI62gXrPpp7ZeE1OnCqz_Dm-T1G3z9--Hb5ubr98un68v1tZVjLWEXWrRGs5dZZzoVxtZBNTTWVBqRqxFoRqomExjhhhQDNpa6dIpY35XLmCDtGJzvvmOLDDHnqtnFOQ_myo5QLzoloZaFOd5RJMecErhuTD6VKR-rud_6u5O_-5C_su2fjrAPYF_Jv7wKc74BH38Pyf1N3fXO1Uz4BZz6SLA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2267661759</pqid></control><display><type>article</type><title>Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Mauzo, Shakuntala H. ; Tetzlaff, Michael T. ; Nelson, Kelly ; Amaria, Rodabe ; Patel, Sapna ; Aung, Phyu P. ; Nagarajan, Priyadharsini ; Torres‐Cabala, Carlos A. ; Diab, Adi ; Prieto, Victor G. ; Curry, Jonathan L.</creator><creatorcontrib>Mauzo, Shakuntala H. ; Tetzlaff, Michael T. ; Nelson, Kelly ; Amaria, Rodabe ; Patel, Sapna ; Aung, Phyu P. ; Nagarajan, Priyadharsini ; Torres‐Cabala, Carlos A. ; Diab, Adi ; Prieto, Victor G. ; Curry, Jonathan L.</creatorcontrib><description>Background
Immune checkpoint antibody blockade is an emerging therapeutic option for treating certain cancers including melanoma. This therapy is associated with dermatologic and systemic toxicities, some of which are more severe than others and may require withholding therapy.
Case reports
We report two patients with melanocytic nevi that regressed with pembrolizumab therapy. The first patient had stage IV BRAF K601E/L584F mutant melanoma that developed a regressed melanocytic nevus while being treated with pembrolizumab. The second patient had stage III BRAF V600R mutant melanoma that was treated with pembrolizumab and dabrafenib, and also developed a regressed melanocytic nevus. Both patients had good response to therapy and stable disease at 8 and 12 months of treatment, respectively.
Results
Regressed melanocytic nevi were observed in both patients treated with pembrolizumab for advance‐stage melanoma. Immunohistochemical analysis of a regressed melanocytic nevus was associated with an inflammatory infiltrate rich in CD8+ T cells and CD163+, CD11c+ histiocytes.
Conclusion
Regressed melanocytic nevi are an emerging dermatologic effect from pembrolizumab therapy.</description><identifier>ISSN: 0011-9059</identifier><identifier>EISSN: 1365-4632</identifier><identifier>DOI: 10.1111/ijd.13833</identifier><identifier>PMID: 29152725</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Aged ; Aged, 80 and over ; Antibodies ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antineoplastic Agents, Immunological - administration & dosage ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biopsy ; Case reports ; CD11c antigen ; CD163 antigen ; CD8 antigen ; Dermoscopy ; Diagnosis, Differential ; Humans ; Immune checkpoint ; Immunotherapy ; Inflammation ; Lymphocytes ; Lymphocytes T ; Male ; Medical treatment ; Melanocytes - drug effects ; Melanocytes - pathology ; Melanoma ; Melanoma - drug therapy ; Melanoma - genetics ; Melanoma - pathology ; Monoclonal antibodies ; Mutation ; Neoplasm Staging ; Nevus ; Nevus, Pigmented - chemically induced ; Nevus, Pigmented - immunology ; Nevus, Pigmented - pathology ; Patients ; Pembrolizumab ; Proto-Oncogene Proteins B-raf - genetics ; Regression analysis ; Skin - diagnostic imaging ; Skin - immunology ; Skin - pathology ; Skin Neoplasms - drug therapy ; Skin Neoplasms - genetics ; Skin Neoplasms - pathology ; Therapy ; Toxicity ; Treatment Outcome</subject><ispartof>International journal of dermatology, 2019-09, Vol.58 (9), p.1045-1052</ispartof><rights>2017</rights><rights>2017 The International Society of Dermatology.</rights><rights>International Journal of Dermatology © 2019 International Society of Dermatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-185c7356dfd667cf079402b29ce9a478a12b19e4cf7d77eb69b0fa1d647253f13</citedby><cites>FETCH-LOGICAL-c3533-185c7356dfd667cf079402b29ce9a478a12b19e4cf7d77eb69b0fa1d647253f13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijd.13833$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijd.13833$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29152725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mauzo, Shakuntala H.</creatorcontrib><creatorcontrib>Tetzlaff, Michael T.</creatorcontrib><creatorcontrib>Nelson, Kelly</creatorcontrib><creatorcontrib>Amaria, Rodabe</creatorcontrib><creatorcontrib>Patel, Sapna</creatorcontrib><creatorcontrib>Aung, Phyu P.</creatorcontrib><creatorcontrib>Nagarajan, Priyadharsini</creatorcontrib><creatorcontrib>Torres‐Cabala, Carlos A.</creatorcontrib><creatorcontrib>Diab, Adi</creatorcontrib><creatorcontrib>Prieto, Victor G.</creatorcontrib><creatorcontrib>Curry, Jonathan L.</creatorcontrib><title>Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade</title><title>International journal of dermatology</title><addtitle>Int J Dermatol</addtitle><description>Background
Immune checkpoint antibody blockade is an emerging therapeutic option for treating certain cancers including melanoma. This therapy is associated with dermatologic and systemic toxicities, some of which are more severe than others and may require withholding therapy.
Case reports
We report two patients with melanocytic nevi that regressed with pembrolizumab therapy. The first patient had stage IV BRAF K601E/L584F mutant melanoma that developed a regressed melanocytic nevus while being treated with pembrolizumab. The second patient had stage III BRAF V600R mutant melanoma that was treated with pembrolizumab and dabrafenib, and also developed a regressed melanocytic nevus. Both patients had good response to therapy and stable disease at 8 and 12 months of treatment, respectively.
Results
Regressed melanocytic nevi were observed in both patients treated with pembrolizumab for advance‐stage melanoma. Immunohistochemical analysis of a regressed melanocytic nevus was associated with an inflammatory infiltrate rich in CD8+ T cells and CD163+, CD11c+ histiocytes.
Conclusion
Regressed melanocytic nevi are an emerging dermatologic effect from pembrolizumab therapy.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antineoplastic Agents, Immunological - administration & dosage</subject><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Biopsy</subject><subject>Case reports</subject><subject>CD11c antigen</subject><subject>CD163 antigen</subject><subject>CD8 antigen</subject><subject>Dermoscopy</subject><subject>Diagnosis, Differential</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immunotherapy</subject><subject>Inflammation</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Melanocytes - drug effects</subject><subject>Melanocytes - pathology</subject><subject>Melanoma</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - genetics</subject><subject>Melanoma - pathology</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Neoplasm Staging</subject><subject>Nevus</subject><subject>Nevus, Pigmented - chemically induced</subject><subject>Nevus, Pigmented - immunology</subject><subject>Nevus, Pigmented - pathology</subject><subject>Patients</subject><subject>Pembrolizumab</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Regression analysis</subject><subject>Skin - diagnostic imaging</subject><subject>Skin - immunology</subject><subject>Skin - pathology</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - genetics</subject><subject>Skin Neoplasms - pathology</subject><subject>Therapy</subject><subject>Toxicity</subject><subject>Treatment Outcome</subject><issn>0011-9059</issn><issn>1365-4632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LHTEUQIMo-mq76B8oAVcuRifJTPLirmg_FKFQ2vWQj5tnnpPJmMxUpn-jf9i0zwpd9G7ChcMJ9yD0ltRnpMy539ozwtaM7aEVYbytGs7oPlrVNSGVrFt5hF7lvC0ro6Q5REdUkpYK2q7Qr6-wSZAzWBygV0M0y-QNHuCHxxlMHKxKC54iHiHoFHv_cw5K4-kOkhqXC6wGDAHSxg-bfwQWUlBT7OOmLOAcmAm7FAP2IcwDYHMH5n6MfpiKYvI62gXrPpp7ZeE1OnCqz_Dm-T1G3z9--Hb5ubr98un68v1tZVjLWEXWrRGs5dZZzoVxtZBNTTWVBqRqxFoRqomExjhhhQDNpa6dIpY35XLmCDtGJzvvmOLDDHnqtnFOQ_myo5QLzoloZaFOd5RJMecErhuTD6VKR-rud_6u5O_-5C_su2fjrAPYF_Jv7wKc74BH38Pyf1N3fXO1Uz4BZz6SLA</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Mauzo, Shakuntala H.</creator><creator>Tetzlaff, Michael T.</creator><creator>Nelson, Kelly</creator><creator>Amaria, Rodabe</creator><creator>Patel, Sapna</creator><creator>Aung, Phyu P.</creator><creator>Nagarajan, Priyadharsini</creator><creator>Torres‐Cabala, Carlos A.</creator><creator>Diab, Adi</creator><creator>Prieto, Victor G.</creator><creator>Curry, Jonathan L.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>201909</creationdate><title>Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade</title><author>Mauzo, Shakuntala H. ; Tetzlaff, Michael T. ; Nelson, Kelly ; Amaria, Rodabe ; Patel, Sapna ; Aung, Phyu P. ; Nagarajan, Priyadharsini ; Torres‐Cabala, Carlos A. ; Diab, Adi ; Prieto, Victor G. ; Curry, Jonathan L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-185c7356dfd667cf079402b29ce9a478a12b19e4cf7d77eb69b0fa1d647253f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antineoplastic Agents, Immunological - administration & dosage</topic><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Biopsy</topic><topic>Case reports</topic><topic>CD11c antigen</topic><topic>CD163 antigen</topic><topic>CD8 antigen</topic><topic>Dermoscopy</topic><topic>Diagnosis, Differential</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immunotherapy</topic><topic>Inflammation</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Melanocytes - drug effects</topic><topic>Melanocytes - pathology</topic><topic>Melanoma</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - genetics</topic><topic>Melanoma - pathology</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Neoplasm Staging</topic><topic>Nevus</topic><topic>Nevus, Pigmented - chemically induced</topic><topic>Nevus, Pigmented - immunology</topic><topic>Nevus, Pigmented - pathology</topic><topic>Patients</topic><topic>Pembrolizumab</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Regression analysis</topic><topic>Skin - diagnostic imaging</topic><topic>Skin - immunology</topic><topic>Skin - pathology</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - genetics</topic><topic>Skin Neoplasms - pathology</topic><topic>Therapy</topic><topic>Toxicity</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mauzo, Shakuntala H.</creatorcontrib><creatorcontrib>Tetzlaff, Michael T.</creatorcontrib><creatorcontrib>Nelson, Kelly</creatorcontrib><creatorcontrib>Amaria, Rodabe</creatorcontrib><creatorcontrib>Patel, Sapna</creatorcontrib><creatorcontrib>Aung, Phyu P.</creatorcontrib><creatorcontrib>Nagarajan, Priyadharsini</creatorcontrib><creatorcontrib>Torres‐Cabala, Carlos A.</creatorcontrib><creatorcontrib>Diab, Adi</creatorcontrib><creatorcontrib>Prieto, Victor G.</creatorcontrib><creatorcontrib>Curry, Jonathan L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>International journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mauzo, Shakuntala H.</au><au>Tetzlaff, Michael T.</au><au>Nelson, Kelly</au><au>Amaria, Rodabe</au><au>Patel, Sapna</au><au>Aung, Phyu P.</au><au>Nagarajan, Priyadharsini</au><au>Torres‐Cabala, Carlos A.</au><au>Diab, Adi</au><au>Prieto, Victor G.</au><au>Curry, Jonathan L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade</atitle><jtitle>International journal of dermatology</jtitle><addtitle>Int J Dermatol</addtitle><date>2019-09</date><risdate>2019</risdate><volume>58</volume><issue>9</issue><spage>1045</spage><epage>1052</epage><pages>1045-1052</pages><issn>0011-9059</issn><eissn>1365-4632</eissn><abstract>Background
Immune checkpoint antibody blockade is an emerging therapeutic option for treating certain cancers including melanoma. This therapy is associated with dermatologic and systemic toxicities, some of which are more severe than others and may require withholding therapy.
Case reports
We report two patients with melanocytic nevi that regressed with pembrolizumab therapy. The first patient had stage IV BRAF K601E/L584F mutant melanoma that developed a regressed melanocytic nevus while being treated with pembrolizumab. The second patient had stage III BRAF V600R mutant melanoma that was treated with pembrolizumab and dabrafenib, and also developed a regressed melanocytic nevus. Both patients had good response to therapy and stable disease at 8 and 12 months of treatment, respectively.
Results
Regressed melanocytic nevi were observed in both patients treated with pembrolizumab for advance‐stage melanoma. Immunohistochemical analysis of a regressed melanocytic nevus was associated with an inflammatory infiltrate rich in CD8+ T cells and CD163+, CD11c+ histiocytes.
Conclusion
Regressed melanocytic nevi are an emerging dermatologic effect from pembrolizumab therapy.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>29152725</pmid><doi>10.1111/ijd.13833</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0011-9059 |
| ispartof | International journal of dermatology, 2019-09, Vol.58 (9), p.1045-1052 |
| issn | 0011-9059 1365-4632 |
| language | eng |
| recordid | cdi_proquest_journals_2267661759 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Aged Aged, 80 and over Antibodies Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biopsy Case reports CD11c antigen CD163 antigen CD8 antigen Dermoscopy Diagnosis, Differential Humans Immune checkpoint Immunotherapy Inflammation Lymphocytes Lymphocytes T Male Medical treatment Melanocytes - drug effects Melanocytes - pathology Melanoma Melanoma - drug therapy Melanoma - genetics Melanoma - pathology Monoclonal antibodies Mutation Neoplasm Staging Nevus Nevus, Pigmented - chemically induced Nevus, Pigmented - immunology Nevus, Pigmented - pathology Patients Pembrolizumab Proto-Oncogene Proteins B-raf - genetics Regression analysis Skin - diagnostic imaging Skin - immunology Skin - pathology Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - pathology Therapy Toxicity Treatment Outcome |
| title | Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T20%3A34%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regressed%20melanocytic%20nevi%20secondary%20to%20pembrolizumab%20therapy:%20an%20emerging%20melanocytic%20dermatologic%20effect%20from%20immune%20checkpoint%20antibody%20blockade&rft.jtitle=International%20journal%20of%20dermatology&rft.au=Mauzo,%20Shakuntala%20H.&rft.date=2019-09&rft.volume=58&rft.issue=9&rft.spage=1045&rft.epage=1052&rft.pages=1045-1052&rft.issn=0011-9059&rft.eissn=1365-4632&rft_id=info:doi/10.1111/ijd.13833&rft_dat=%3Cproquest_cross%3E2267661759%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2267661759&rft_id=info:pmid/29152725&rfr_iscdi=true |